Pfizer stock faced challenges in 2024 but shows potential for growth in 2025
From Nasdaq: 2025-01-15 22:52:44
In 2024, Pfizer stock (NYSE: PFE) underperformed, losing 5% while the S&P 500 gained 23%. Factors like declining Covid-19 vaccine sales and increased competition impacted Pfizer’s performance. Despite challenges, the company saw growth in sales excluding Covid-19 products and made efforts to improve profitability by cutting costs and reducing debt.
PFE stock declined in 2024 but could see a recovery in 2025. Pfizer’s focus on improving profitability and the potential for increased earnings growth may drive stock value. With a valuation estimate of $36 per share, there is optimism for a 40% upside. Initiatives like boosting profitability and growing market share for key drugs could fuel growth.
In 2025, Pfizer faces challenges like the loss of patent protection for Xeljanz but also opportunities for growth with drugs like Vyndaqel, Abrysvo, and Eliquis. The company’s Covid-19 vaccine, Comirnaty, approved to combat newer variants, will also impact performance. Investors will be watching for signs of improved profitability, with PFE stock trading below average P/S ratio.
Pfizer’s performance in 2024 and outlook for 2025 suggest a mix of challenges and opportunities. While PFE stock appears undervalued, comparisons with peers can provide valuable insights. For a smoother ride and potential upside, consider diversifying with a high-quality portfolio that outperformed the S&P 500 and delivered strong returns since inception. 1. The unemployment rate in the United States has decreased to 5.9% in September, down from 6.1% in August. The economy added 194,000 jobs last month, exceeding expectations. This marks a positive trend in the labor market recovery following the impact of the pandemic.
2. In other news, the stock market saw a significant increase today, with the S&P 500 reaching a new record high. Tech stocks led the way, with companies like Apple and Amazon posting strong gains. Investors are optimistic about the economic outlook and corporate earnings.
3. The FDA has approved the use of a new COVID-19 treatment pill developed by Merck. The pill, called molnupiravir, has shown promising results in reducing the severity of symptoms and hospitalizations in clinical trials. This marks a significant advancement in the fight against the pandemic.
Read more at Nasdaq: What’s In Store For PFE Stock In 2025?